SCHEMBL3055296

SCHEMBL3055296

Cc1cccc(OCC(=O)N(C)C2CCN(C)CC2)c1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.67
KMT2A Q03164 7/20 0.48
MEN1 O00255 5/20 0.48
ALDH1A1 P00352 4/20 0.48
TSHR P16473 1/20 0.48
THRB P10828 1/20 0.47
LMNA P02545 1/20 0.44
USP2 O75604 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
NR4A1 P22736 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TP53 P04637 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3047625 0.83 POLB (0.70) POLBKMT2AALDH1A1LMNAMAPT
SCHEMBL3051897 0.83 POLB (0.73) POLBKMT2AMEN1ALDH1A1TSHR
SCHEMBL3049283 0.82 POLB (0.65) POLBKMT2AMEN1ALDH1A1LMNA
SCHEMBL3042587 0.82 POLB (0.69) POLBKMT2AMEN1ALDH1A1TSHR
SCHEMBL3050521 0.82 POLB (0.71) POLBKMT2AMEN1ALDH1A1LMNA
SCHEMBL3047425 0.77 MAPT (0.62) POLBKMT2AMAPTHTR2AHTR2C
SCHEMBL4340461 0.76 POLB (0.57) POLBKMT2AMEN1ALDH1A1LMNA
SCHEMBL3038901 0.75 RAB9A (0.60) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL3047421 0.74 POLB (0.60) POLBKMT2AMEN1ALDH1A1USP2
SCHEMBL3047069 0.73 POLB (0.57) POLBKMT2AMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1434765-B1 SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR HIGH POINT PHARMACEUTICALS LLC (US) 2009-12-02 EP claimed
US-20100222386-A1 SUBSTITUTED PIPERIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-20100222386-A1 SUBSTITUTED PIPERIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-20100222386-A1 SUBSTITUTED PIPERIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-7767695-B2 Substituted piperidines HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-03 US disclosed
US-7767695-B2 Substituted piperidines HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-03 US disclosed
US-7767695-B2 Substituted piperidines HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-03 US disclosed
EP-1434765-B1 SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR HIGH POINT PHARMACEUTICALS LLC (US) 2009-12-02 EP disclosed
EP-1434765-B1 SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR HIGH POINT PHARMACEUTICALS LLC (US) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222386-A1 SUBSTITUTED PIPERIDINES HRH3, HRH4, HRH2 POLB 3476/4885KMT2A 513/4885MEN1 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.